Quarterly Earnings

The specialty chemicals firm saw a full-year revenue dip but ended 2025 with strong cash flow and signs of a turnaround in its struggling divisions.

Hecla Mining posts a record $1.4B year, slashes debt, and sells a major gold mine to double down on its strategy to dominate the North American silver market.

RV giant THOR Industries' upcoming Q2 earnings are a critical test for consumer spending as interest rate cuts battle cautious sentiment and market shifts.

With strong growth and a high valuation, BrightSpring's upcoming Investor Day is a key moment to outline its strategy for profitability and market leadership.

The gas giant posts huge profits and production growth in its first year post-merger, charting a course for massive debt reduction and shareholder returns.

As Jazz Pharmaceuticals preps for key investor talks, all eyes are on its blockbuster pipeline, revenue growth, and strategy to fend off competition.

Facing massive revenue declines and a shrinking coach network due to GLP-1 drugs, Medifast bets its future on a risky pivot from weight loss to metabolic health.

With a major earnings call set for Feb. 23, Lincoln Educational Services' 2025 results will reveal if its aggressive expansion meets soaring market demand.

Havas reports 3.1% organic growth, driven by its Converged.AI platform and a series of key acquisitions, positioning it as a tech-forward industry leader.

Following a year of robust earnings and a 10% dividend hike, Great-West Lifeco's CEO is set to detail the firm's future plans in a key investor chat.

As KP Tissue prepares to release Q4 2025 results, all eyes are on Kruger Products' performance after a year of major strategic investments and expansion.

LiveRamp adds Uber's ad chief and retail media architect Kristi Argyilan to its board, signaling a major push into the future of AI-driven commerce media.

As Revvity execs prepare for key conferences, investors will watch for clues on AI strategy, growth guidance, and margin recovery after a mixed 2025.

At a key conference, DocGo's CEO will navigate financial headwinds while promoting a vision for proactive, tech-enabled healthcare delivery.

Fresh off its IPO, Lumexa Imaging's leadership heads to key conferences. Here’s what’s at stake as they pitch their growth strategy to investors.

Ahead of its March 3 earnings call, 908 Devices' strong preliminary results and focus on handheld tech signal a pivotal year for the security innovator.

Fresh off a $1.1B IPO and a #1 GreenTech ranking, BETA Technologies faces investors to prove its electric aviation vision is commercially viable.

Fortrea splits key roles, dedicating its CMO to scientific strategy and hiring a new president for clinical pharmacology in a bold post-spin-off move.

As firms face a data deluge and new rules, Normative's new service outsources the heavy lifting of carbon accounting for overstretched teams.

Disc Medicine's promising EPP drug hits a major roadblock as the FDA seeks more data, delaying hope for patients and setting up a high-stakes trial.